Undisclosed Ophthalmology Program(s)
Likely retinal diseases (e.g., AMD, DME) or glaucoma
Pre-clinicalActive
Key Facts
Indication
Likely retinal diseases (e.g., AMD, DME) or glaucoma
Phase
Pre-clinical
Status
Active
Company
About Interstice Therapeutics
Interstice Therapeutics is a private, early-stage biotech founded in 2021 and based in Cambridge, MA, operating at the intersection of ophthalmology and drug delivery. The company employs a capital-efficient 505(b)(2) regulatory strategy to develop modified versions of approved drugs, targeting specific adoption gaps in the market. This approach is designed to reduce clinical development time and risk compared to novel New Drug Applications (NDAs). As a pre-revenue company, its success hinges on advancing its pipeline through clinical development and securing strategic partnerships or funding.
View full company profile